• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: W. L. GORE & ASSOCIATES, INC. GORE® EXCLUDER® AAA ENDOPROSTHESIS; SYSTEM, ENDOVASCULAR GRAFT, AORTIC ANEURYSM TREATMENT

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

W. L. GORE & ASSOCIATES, INC. GORE® EXCLUDER® AAA ENDOPROSTHESIS; SYSTEM, ENDOVASCULAR GRAFT, AORTIC ANEURYSM TREATMENT Back to Search Results
Catalog Number PLC271200
Medical Device Problem Code Device Endoleak (4074)
Health Effect - Clinical Codes Aneurysm expansion (4597); Clinical Endoleak (4843)
Date of Event 03/05/2026
Type of Reportable Event Serious Injury
Event or Problem Description
The following was reported to gore on march 30, 2026, from a tgr alert notification.On (b)(6) 2025, the patient underwent endovascular treatment as a planned endovascular procedure for an aortoiliac aneurysm.The patient was treated with the gore® excluder® aaa endoprosthesis and gore® excluder® conformable aaa endoprosthesis.The gore® devices were successfully implanted.The patient was discharged on (b)(6) 2025.On (b)(6) 2025, the patient underwent a cta, which revealed a type ii endoleak.On (b)(6) 2026, the patient underwent a cta, which revealed a type ii endoleak and aneurysm sac enlargement.The aneurysm increased in size by 3mm.On (b)(6) 2026, a coil embolization was performed to treat the type ii endoleak.The procedure involved selective cannulation of a lumbar segmental branch arising from the posterior division of the left internal iliac artery that was feeding the aneurysm sac, followed by deployment of two penumbra coils.Post-embolization angiography and completion aortography demonstrated no further filling of the aneurysm sac.The patient tolerated the procedure.
 
Additional Manufacturer Narrative
W.L.Gore & associates, inc.(gore) is submitting this report to comply with 21 c.F.R.Part 803, the medical device reporting regulation.This report is based upon information obtained by gore, which the company may not have been able to fully investigate or verify prior to the date the report was required by the fda.Blank fields present on this report include required fields and fields determined to be not applicable.Blank required fields indicate that the information was not provided, was deemed unavailable or was not applicable.This report does not constitute an admission or a conclusion by fda, gore, or its associates that the device, gore or its associates caused or contributed to the event described in the report.In particular, this report does not constitute a legal admission by anyone that the product described in this report has any defects or has malfunctioned, as defined from a legal standpoint.These words are included in the report and are fixed items for selection created by the fda, to categorize the type of event solely for the purpose of reporting pursuant to part 803.This statement should be included with any information or report disclosed to the public under the freedom of information act.
 
Additional Manufacturer Narrative
Added b5, g3/g4, h1/h2.
 
Event or Problem Description
On (b)(6), the patient underwent a cta, which revealed a type ii endoleak.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
GORE® EXCLUDER® AAA ENDOPROSTHESIS
Common Device Name
SYSTEM, ENDOVASCULAR GRAFT, AORTIC ANEURYSM TREATMENT
Manufacturer (Section D)
W. L. GORE & ASSOCIATES, INC.
1505 n. fourth street
flagstaff AZ 86004
Manufacturer (Section G)
MEDICAL SILICON VALLEY B/P
2890 de la cruz blvd.
santa clara CA 95050
Manufacturer Contact
monique nwanze
1505 n. fourth street
flagstaff, AZ 86004
9285263030
MDR Report Key24876309
Report Number3013164176-2026-02976
Device Sequence Number21107352
Product Code MIH
UDI-Device Identifier00733132618545
UDI-Public(01)00733132618545(17)280525
Combination Product (Y/N)N
Initial Reporter StateLA
Initial Reporter CountryUS
PMA/510(K) Number
P200030
Number of Events Summarized1
Summary Report (Y/N)N
Device Implanted Year2025
Serviced by Third Party (Y/N)N
Reporter Type Manufacturer
Report Source Study
Initial Reporter Occupation Physician
Type of Report Initial,Followup
Report Date (Section B) 04/28/2026
1 Device was Involved in the Event
1 Patient was Involved in the Event
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Operator of Device Health Professional
Device Catalogue NumberPLC271200
Was Device Available for Evaluation? No
Is the Reporter a Health Professional? Yes
Type of Report(Section G)Thirty-Day
Initial Date Received by Manufacturer 03/30/2026
Supplement Date Received by Manufacturer04/24/2026
Initial Report FDA Received Date04/14/2026
Supplement Report FDA Received Date04/28/2026
Was Device Evaluated by Manufacturer? (Y/N) No
Date Device Manufactured05/27/2025
Is the Device Labeled for Single Use? (Y/N) Yes
Usage of Device Initial
Patient Sequence Number1
Concomitant Medical Products
and Therapy/Usage Dates
MEDICATIONS: HYPERCHOLESTEROLEMIA, HYPERTENSION
Outcome Attributed to Adverse Event Required Intervention;
Patient Age66 YR
Patient SexMale
Patient EthnicityNon Hispanic
Patient RaceWhite
-
-